Bridgewood, C orcid.org/0000-0002-3083-3076, Alase, A, Watad, A et al. (3 more authors) (2019) The IL-23p19/EBI3 heterodimeric cytokine termed IL-39 remains a theoretical cytokine in man. Inflammation Research, 68 (6). pp. 423-426. ISSN 1023-3830
Abstract
Objective: The heterodimeric IL-12 family member cytokines including, IL-12, IL-23, IL-27, and IL-35 and have multiple roles in regulating innate and adaptive immunity with crucial functions in inflammatory disorders such as psoriasis. Chain pairing promiscuity is a feature of the IL-12 family. Recently, based on murine data, a new family member, IL-39, was proposed, consisting of IL23p19 (shared with IL-23) and EBI3 (shared with IL-27 and IL-35). IL-39 has subsequently been implicated in experimental murine lupus. Given the success of IL-23p19 therapeutic targeting in diseases including psoriasis, it is of great interest to confirm the presence of IL-39 in man. Human IL-39 is yet to be either detected or expressed, which has halted research in this area. Methods: Using a disulphide-linked human chimera protein composing of IL-23p19 and EBI3 human chains, we stimulated human leukocytes, and analysed cytokine secretion and STAT3 phosphorylation. Results and Conclusion: We report that this cytokine shows no activity in human cells. IL-39 chimera protein failed to induce either IL-6, IL-8, TNF, or IL-17A from leukocytes or STAT3 phosphorylation and thus, remains a ‘theoretical cytokine' in humans.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
Keywords: | Cytokine · IL-23 · Lupus · Psoriasis · IL-39 |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Experimental Musculoskeletal Medicine (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 15 May 2019 14:19 |
Last Modified: | 15 May 2019 14:19 |
Status: | Published |
Publisher: | Springer |
Identification Number: | 10.1007/s00011-019-01235-x |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:146093 |
Commentary/Response Threads
- Bridgewood, C, Alase, A, Watad, A, Wittmann, M, Cuthbert, R and McGonagle, D The IL-23p19/EBI3 heterodimeric cytokine termed IL-39 remains a theoretical cytokine in man. (deposited 15 May 2019 14:19) [Currently Displayed]
Download
Filename: Bridgewood2019_Article_TheIL-23p19EBI3HeterodimericCy.pdf
Licence: CC-BY 4.0